ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

Compare

2,368 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ACAD Analyst Ratings

Moderate Buy

13 Buy

5 Hold

1 Sell

Based on 19 analysts giving stock ratings to

ACADIA

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ACAD Stock 12 Month Forecast

Average Price Target

$29.06

▲(24.88%Upside)

Based on 19 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $29.06 with a high forecast of $39.00 and a low forecast of $15.00. The average price target represents a 24.88% change from the last price of $23.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","40":"$40","19.75":"$19.75","26.5":"$26.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,19.75,26.5,33.25,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.36,22.716923076923077,24.073846153846155,25.43076923076923,26.787692307692307,28.144615384615385,29.50153846153846,30.858461538461537,32.215384615384615,33.57230769230769,34.92923076923077,36.286153846153844,37.64307692307692,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.36,21.95230769230769,22.544615384615383,23.136923076923075,23.729230769230767,24.32153846153846,24.91384615384615,25.506153846153843,26.098461538461535,26.690769230769227,27.28307692307692,27.875384615384615,28.467692307692307,{"y":29.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.36,20.87076923076923,20.38153846153846,19.892307692307693,19.403076923076924,18.913846153846155,18.424615384615386,17.935384615384613,17.446153846153845,16.956923076923076,16.467692307692307,15.978461538461538,15.489230769230769,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.1,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.04,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$39.00

Average Price Target$29.06

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$25

Buy

7.43%

Upside

Reiterated

06/11/25

ACADIA Pharmaceuticals displays robust financial performance and momentum, supported by strong product sales and strategic growth initiatives. Legal victories reinforce its market position. Increased R&D spending and sales volatility present minor risks, but the overall outlook remains positive.

Tessa RomeroJ.P. Morgan

J.P. Morgan

$30→$34

Buy

46.11%

Upside

Reiterated

07/24/25

ACADIA Pharmaceuticals (ACAD) Receives a Buy from J.P. MorganJPMorgan analyst Tessa Romero raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 (from $30.00) while maintaining a Overweight rating.

Sean LaamanMorgan Stanley

Morgan Stanley

$24

Hold

3.14%

Upside

Reiterated

07/21/25

Cautious Outlook on ACADIA Pharmaceuticals Amid Market Penetration and Growth UncertaintiesWe will look for: (1) metrics to evaluate Daybue sales performance in North America; (2) commentary on Nuplazid's growth potential after patent protection; and (3) confirmation of pipeline catalysts.

Tazeen AhmadBank of America Securities

Bank of America Securities

$23

Hold

-1.16%

Downside

Reiterated

07/15/25

Bank of America Securities Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD)

Marc GoodmanLeerink Partners

Leerink Partners

$28→$32

Buy

37.52%

Upside

Reiterated

07/11/25

Leerink Partners Remains a Buy on ACADIA Pharmaceuticals (ACAD)

Evan SeigermanBMO Capital

BMO Capital

$28

Buy

20.33%

Upside

Reiterated

07/09/25

BMO Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)

Brian AbrahamsRBC Capital

RBC Capital

$38→$39

Buy

67.60%

Upside

Reiterated

07/07/25

RBC Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

Ritu BaralTD Cowen

TD Cowen

$35

Buy

50.41%

Upside

Reiterated

06/27/25

ACADIA Pharmaceuticals (ACAD) Gets a Buy from TD Cowen

Ashwani VermaUBS

UBS

$22→$32

Buy

37.52%

Upside

Reiterated

06/27/25

UBS Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

Ami FadiaNeedham

Needham

$30

Buy

28.92%

Upside

Reiterated

06/26/25

Analysts' Top Healthcare Picks: Cognition Therapeutics (CGTX), ACADIA Pharmaceuticals (ACAD)

Salveen RichterGoldman Sachs

Goldman Sachs

$15

Sell

-35.54%

Downside

Reiterated

06/26/25

ACADIA Pharmaceuticals (ACAD) Gets a Sell from Goldman Sachs

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$32

Buy

37.52%

Upside

Reiterated

06/26/25

Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)

Jason ButlerCitizens JMP

Citizens JMP

$37

Buy

59.00%

Upside

Reiterated

06/26/25

Citizens JMP reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

Ananda GhoshH.C. Wainwright

H.C. Wainwright

$27→$32

Buy

37.52%

Upside

Reiterated

06/26/25

H.C. Wainwright Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

Matthew HershenhornOppenheimer

Oppenheimer

$19→$22

Hold

-5.46%

Downside

Reiterated

06/26/25

Acadia Pharmaceuticals price target raised to $22 from $19 at OppenheimerAcadia Pharmaceuticals price target raised to $22 from $19 at Oppenheimer

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$25

Buy

7.43%

Upside

Reiterated

06/11/25

Tessa RomeroJ.P. Morgan

J.P. Morgan

$30→$34

Buy

46.11%

Upside

Reiterated

07/24/25

Sean LaamanMorgan Stanley

Morgan Stanley

$24

Hold

3.14%

Upside

Reiterated

07/21/25

Tazeen AhmadBank of America Securities

Bank of America Securities

$23

Hold

-1.16%

Downside

Reiterated

07/15/25

Bank of America Securities Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD)

Marc GoodmanLeerink Partners

Leerink Partners

$28→$32

Buy

37.52%

Upside

Reiterated

07/11/25

Leerink Partners Remains a Buy on ACADIA Pharmaceuticals (ACAD)

Evan SeigermanBMO Capital

BMO Capital

$28

Buy

20.33%

Upside

Reiterated

07/09/25

BMO Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)

Brian AbrahamsRBC Capital

RBC Capital

$38→$39

Buy

67.60%

Upside

Reiterated

07/07/25

RBC Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

Ritu BaralTD Cowen

TD Cowen

$35

Buy

50.41%

Upside

Reiterated

06/27/25

ACADIA Pharmaceuticals (ACAD) Gets a Buy from TD Cowen

Ashwani VermaUBS

UBS

$22→$32

Buy

37.52%

Upside

Reiterated

06/27/25

UBS Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

Ami FadiaNeedham

Needham

$30

Buy

28.92%

Upside

Reiterated

06/26/25

Analysts' Top Healthcare Picks: Cognition Therapeutics (CGTX), ACADIA Pharmaceuticals (ACAD)

Salveen RichterGoldman Sachs

Goldman Sachs

$15

Sell

-35.54%

Downside

Reiterated

06/26/25

ACADIA Pharmaceuticals (ACAD) Gets a Sell from Goldman Sachs

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$32

Buy

37.52%

Upside

Reiterated

06/26/25

Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)

Jason ButlerCitizens JMP

Citizens JMP

$37

Buy

59.00%

Upside

Reiterated

06/26/25

Ananda GhoshH.C. Wainwright

H.C. Wainwright

$27→$32

Buy

37.52%

Upside

Reiterated

06/26/25

H.C. Wainwright Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)

Matthew HershenhornOppenheimer

Oppenheimer

$19→$22

Hold

-5.46%

Downside

Reiterated

06/26/25

Acadia Pharmaceuticals price target raised to $22 from $19 at OppenheimerAcadia Pharmaceuticals price target raised to $22 from $19 at Oppenheimer

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ACADIA Pharmaceuticals

1 Month

xxx

Success Rate

15/27 ratings generated profit

Average Return

+1.49%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +1.49% per trade.

3 Months

xxx

Success Rate

18/28 ratings generated profit

Average Return

+7.28%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +7.28% per trade.

1 Year

Ritu BaralTD Cowen

Success Rate

19/28 ratings generated profit

Average Return

+10.05%

reiterated a buy rating 29 days ago

Copying Ritu Baral's trades and holding each position for 1 Year would result in 67.86% of your transactions generating a profit, with an average return of +10.05% per trade.

2 Years

xxx

Success Rate

13/29 ratings generated profit

Average Return

+4.14%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 44.83% of your transactions generating a profit, with an average return of +4.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACAD Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ACAD has received 40 Buy Ratings, 13 Hold Ratings, and 1 Sell Ratings. ACAD average Analyst price target in the past 3 months is 29.06.

Each month's total comprises the sum of three months' worth of ratings.

ACAD Financial Forecast

ACAD Earnings Forecast

Next quarter’s earnings estimate for ACAD is $0.14 with a range of $0.04 to $0.22. The previous quarter’s EPS was $0.11. ACAD beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year ACAD has Outperformed its overall industry.

ACAD Sales Forecast

Next quarter’s sales forecast for ACAD is $262.09M with a range of $255.90M to $272.58M. The previous quarter’s sales results were $244.32M. ACAD beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year ACAD has Outperformed its overall industry.

ACAD Stock Forecast FAQ

What is ACAD’s average 12-month price target, according to analysts?

Based on analyst ratings, ACADIA Pharmaceuticals Inc.’s 12-month average price target is 29.06.

What is ACAD’s upside potential, based on the analysts’ average price target?

ACADIA Pharmaceuticals Inc. has 24.88% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACAD a Buy, Sell or Hold?

ACADIA Pharmaceuticals Inc. has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 1 sell ratings.

What is ACADIA Pharmaceuticals Inc.’s price target?

The average price target for ACADIA Pharmaceuticals Inc. is 29.06. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $39.00 ,the lowest forecast is $15.00. The average price target represents 24.88% Increase from the current price of $23.27.

What do analysts say about ACADIA Pharmaceuticals Inc.?

ACADIA Pharmaceuticals Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of ACAD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

ACAD Analyst Ratings

ACAD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ACADIA Pharmaceuticals

ACAD Analyst Recommendation Trends

ACAD Financial Forecast

ACAD Earnings Forecast

ACAD Sales Forecast

ACAD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts